These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25977289)

  • 1. An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes.
    Cocco L; Finelli C; Mongiorgi S; Clissa C; Russo D; Bosi C; Quaranta M; Malagola M; Parisi S; Stanzani M; Ramazzotti G; Mariani GA; Billi AM; Manzoli L; Follo MY
    J Leukoc Biol; 2015 Nov; 98(5):769-80. PubMed ID: 25977289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment.
    Follo MY; Russo D; Finelli C; Mongiorgi S; Clissa C; Filì C; Colombi C; Gobbi M; Manzoli L; Piazzi M; Martelli AM; Cocco L
    Leukemia; 2012 May; 26(5):943-50. PubMed ID: 22033492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.
    Follo MY; Finelli C; Mongiorgi S; Clissa C; Chiarini F; Ramazzotti G; Paolini S; Martinelli G; Martelli AM; Cocco L
    Leukemia; 2011 Feb; 25(2):271-80. PubMed ID: 21109771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS.
    Follo MY; Finelli C; Mongiorgi S; Clissa C; Bosi C; Testoni N; Chiarini F; Ramazzotti G; Baccarani M; Martelli AM; Manzoli L; Martinelli G; Cocco L
    Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16811-6. PubMed ID: 19805378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients.
    Follo MY; Mongiorgi S; Clissa C; Paolini S; Martinelli G; Martelli AM; Fioravanti G; Manzoli L; Finelli C; Cocco L
    Leukemia; 2012 Dec; 26(12):2474-82. PubMed ID: 22596089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.
    Filì C; Malagola M; Follo MY; Finelli C; Iacobucci I; Martinelli G; Cattina F; Clissa C; Candoni A; Fanin R; Gobbi M; Bocchia M; Defina M; Spedini P; Skert C; Manzoli L; Cocco L; Russo D
    Clin Cancer Res; 2013 Jun; 19(12):3297-308. PubMed ID: 23596104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.
    Follo MY; Finelli C; Clissa C; Mongiorgi S; Bosi C; Martinelli G; Baccarani M; Manzoli L; Martelli AM; Cocco L
    J Clin Oncol; 2009 Feb; 27(5):782-90. PubMed ID: 19114693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome.
    Follo MY; Bosi C; Finelli C; Fiume R; Faenza I; Ramazzotti G; Gaboardi GC; Manzoli L; Cocco L
    Int J Mol Med; 2006 Aug; 18(2):267-71. PubMed ID: 16820933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear Inositide Signaling Via Phospholipase C.
    Ratti S; Mongiorgi S; Ramazzotti G; Follo MY; Mariani GA; Suh PG; McCubrey JA; Cocco L; Manzoli L
    J Cell Biochem; 2017 Aug; 118(8):1969-1978. PubMed ID: 28106288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS).
    Cappellini A; Mongiorgi S; Finelli C; Fazio A; Ratti S; Marvi MV; Curti A; Salvestrini V; Pellagatti A; Billi AM; Suh PG; McCubrey JA; Boultwood J; Manzoli L; Cocco L; Follo MY
    FASEB J; 2020 Nov; 34(11):15400-15416. PubMed ID: 32959428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
    Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
    Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
    Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
    Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation.
    Mongiorgi S; Follo MY; Yang YR; Ratti S; Manzoli L; McCubrey JA; Billi AM; Suh PG; Cocco L
    Curr Pharm Des; 2016; 22(16):2345-8. PubMed ID: 26916022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia.
    Lo Vasco VR; Calabrese G; Manzoli L; Palka G; Spadano A; Morizio E; Guanciali-Franchi P; Fantasia D; Cocco L
    Leukemia; 2004 Jun; 18(6):1122-6. PubMed ID: 15085153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiology and pathology of nuclear phospholipase C β1.
    Cocco L; Follo MY; Faenza I; Fiume R; Ramazzotti G; Weber G; Martelli AM; Manzoli FA
    Adv Enzyme Regul; 2011; 51(1):2-12. PubMed ID: 21035488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear translocation of PKC-α is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs).
    Poli A; Ratti S; Finelli C; Mongiorgi S; Clissa C; Lonetti A; Cappellini A; Catozzi A; Barraco M; Suh PG; Manzoli L; McCubrey JA; Cocco L; Follo MY
    FASEB J; 2018 Feb; 32(2):681-692. PubMed ID: 28970249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
    Liu HB; Urbanavicius D; Tan P; Spencer A; Dear AE
    Int J Oncol; 2014 Oct; 45(4):1742-8. PubMed ID: 25051119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of nuclear PI-PLCbeta1 during cell differentiation.
    Cocco L; Manzoli L; Faenza I; Ramazzotti G; Yang YR; McCubrey JA; Suh PG; Follo MY
    Adv Biol Regul; 2016 Jan; 60():1-5. PubMed ID: 26525203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.
    Curik N; Burda P; Vargova K; Pospisil V; Belickova M; Vlckova P; Savvulidi F; Necas E; Hajkova H; Haskovec C; Cermak J; Krivjanska M; Trneny M; Laslo P; Jonasova A; Stopka T
    Leukemia; 2012 Aug; 26(8):1804-11. PubMed ID: 22343522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphoinositide phospholipase Cbeta1 (PI-PLCbeta1) gene in myelodysplastic syndromes and cytogenetically normal acute myeloid leukemia: not a deletion, but increased PI-PLCbeta1 expression is an independent prognostic factor.
    Damm F; Lange K; Heuser M; Oberacker T; Morgan M; Wagner K; Krauter J; Schlegelberger B; Ganser A; Göhring G
    J Clin Oncol; 2010 Aug; 28(22):e384-7; author reply e388-9. PubMed ID: 20516454
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.